In the randomized, double-blind trial, investigators assigned children from 9 months to 12 years of age in a 1:1 ratio to receive a single dose of Vi polysaccharide typhoid conjugate vaccine (Vi-TCV) or meningococcal capsular group A conjugate (MenA) vaccine as the control group. The primary outcome was typhoid fever by confirmed blood culture. Vaccine efficacy and safety outcomes were reported after 18 to 24 months of follow-up.
Read more...